Burden of disease caused by keratinocyte cancer has increased in The Netherlands since 1989 - 16/10/14
, Esther de Vries, PhD a, b, c, Mieke J. Aarts, PhD c, Caroline Schroten, PhD d, Tamar E.C. Nijsten, MD, PhD aAbstract |
Background |
Keratinocyte cancer is the most common cancer among Caucasians.
Objective |
We sought to study time trends of the burden of disease attributable to keratinocyte cancer in The Netherlands.
Methods |
Data of all patients with newly diagnosed keratinocyte cancer (ie, squamous cell carcinoma and basal cell carcinoma) were obtained from the population-based Netherlands Cancer Registry and the Eindhoven Cancer Registry (1989-2008). Population structure, mortality data, and life expectancy data were extracted from Statistics Netherlands. The disability-adjusted life-years (DALY) was the sum of the years of life lived with disability and the years of life lost.
Results |
The world standardized rate of keratinocyte cancer has doubled and was 103 and 94 per 100,000 person-years for males and females in 2004 to 2008, respectively. DALYs as a result of basal cell carcinoma increased by 124% and DALYs as a result of squamous cell carcinoma increased by 66% from 1989 to 1993. Keratinocyte cancer accounted for a total loss of 19,913 DALYs (15,369 years of life lived with disability and 4544 years of life lost) between 2004 and 2008.
Limitations |
Only the first keratinocyte cancer was included in this study.
Conclusion |
Keratinocyte cancer is a large burden to the Dutch society. Because incidence rates of keratinocyte cancer continue to increase, the management becomes even more challenging.
Le texte complet de cet article est disponible en PDF.Key words : basal cell carcinoma, burden of disease, cutaneous squamous cell carcinoma, disability-adjusted life-year, keratinocyte cancer, population-based
Abbreviations used : BCC, CI, DALY, NCR, NMSC, SCC, YLD, YLL
Plan
| Funding sources: None. |
|
| Disclosure: Dr Nijsten has been a speaker and part of the advisory board for Leo Pharma and Galderma, and received grants from Leo Pharma, Galderma, Meda Pharma, and Roche. This project, however, was not financially supported by a pharmaceutical company. Drs Hollestein, de Vries, Aarts, and Schroten have no conflicts of interest to declare. |
Vol 71 - N° 5
P. 896-903 - novembre 2014 Retour au numéro
Article précédent
- Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: Implications for genetic counseling
- Miriam Potrony, Joan Anton Puig-Butillé, Paula Aguilera, Celia Badenas, Cristina Carrera, Josep Malvehy, Susana Puig
- An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma
- Mina Sarah Ally, Sumaira Aasi, Ashley Wysong, Claudia Teng, Eric Anderson, Irene Bailey-Healy, Anthony Oro, Jinah Kim, Anne Lynn Chang, Jean Yuh Tang
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?